| Literature DB >> 24500403 |
Abstract
A newly created antibody to the active site of Factor XIIa protects against clotting of extracorporeal bypass circuitry without bleeding risk in vivo, obviating the need for heparin (Larsson et al., this issue).Entities:
Mesh：
Substances：
Year: 2014 PMID： 24500403 DOI： 10.1126/scitranslmed.3008497
Source DB: PubMed Journal: Sci Transl Med ISSN： 1946-6234 Impact factor: 17.956